Literature DB >> 16170596

Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics.

Whei-Mei Wu1, Peter Buchwald, Nobuhiro Mori, Fubao Ji, JiaXiang Wu, Nicholas Bodor.   

Abstract

PURPOSE: This study was conducted to evaluate the zwitterionic common metabolite of a novel series of N-substituted soft analogs of glycopyrrolate both as racemates and as 2R isomers.
METHODS: Activities were assessed using both in vitro (receptor binding assay, guinea pig ileum pA2 assay) and in vivo techniques (rabbit mydriatic response, rat cardiac effects). Pharmacokinetic characterizations in rats were also performed.
RESULTS: The metabolite was highly water-soluble and very stable in buffer solutions as well as in rat biological media. Following i.v. administration in rats, it was very rapidly eliminated, mainly through renal excretion with a half-life of about 10 min. Receptor binding and guinea pig ileum assays indicated this metabolite as more than 1 order of magnitude less active than its parent soft drugs or glycopyrrolate. Moderate M3/M2 muscarinic receptor subtype selectivity was observed, further reducing the likelihood of cardiac side effects. The metabolite showed to some extent mydriatic effect and protective effect against carbachol-induced bradycardia, but of much shorter durations than glycopyrrolate; it had, however, no effect on resting heart rate.
CONCLUSIONS: N-Substituted zwitterionic metabolites retain some, but only considerably reduced activity of their parent quaternary ammonium ester soft anticholinergic drugs, and they are very rapidly eliminated from the systemic circulation. They are suitable for their assigned role within the framework of inactive metabolite-based soft anticholinergic design.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170596     DOI: 10.1007/s11095-005-8174-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  46 in total

Review 1.  Biopharmaceutical considerations in topical ocular drug delivery.

Authors:  N M Davies
Journal:  Clin Exp Pharmacol Physiol       Date:  2000-07       Impact factor: 2.557

2.  Soft drugs. 21. Design and evaluation of soft analogs of propantheline.

Authors:  G Brouillette; M Kawamura; G N Kumar; N Bodor
Journal:  J Pharm Sci       Date:  1996-06       Impact factor: 3.534

Review 3.  Selective muscarinic receptor agonists and antagonists.

Authors:  R M Eglen; N Watson
Journal:  Pharmacol Toxicol       Date:  1996-02

Review 4.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

Authors:  M P Caulfield; N J Birdsall
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

Review 5.  Retrometabolic approaches for drug design and targeting.

Authors:  N Bodor
Journal:  Pharmazie       Date:  1997-07       Impact factor: 1.267

6.  Acute psychosis associated with topical cyclopentolate hydrochloride.

Authors:  A K Khurana; B K Ahluwalia; C Rajan; A K Vohra
Journal:  Am J Ophthalmol       Date:  1988-01-15       Impact factor: 5.258

7.  Stereoselective inhibition of muscarinic receptor subtypes by the eight stereoisomers related to rociverine.

Authors:  P Barbier; A R Renzetti; L Turbanti; C Di Bugno; F Fornai; F Vaglini; R Maggio; G U Corsini
Journal:  Eur J Pharmacol       Date:  1995-07-18       Impact factor: 4.432

8.  Identification of a family of muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; N J Buckley; A C Young; M R Brann
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

9.  Pharmacokinetics of glycopyrronium in uraemic patients.

Authors:  M Kirvelä; T Ali-Melkkilä; T Kaila; E Iisalo; L Lindgren
Journal:  Br J Anaesth       Date:  1993-09       Impact factor: 9.166

10.  Cardiac dysrhythmias associated with ophthalmic atropine.

Authors:  G J Merli; H Weitz; J H Martin; E F McClay; A G Adler; F M Fellin; M Libonati
Journal:  Arch Intern Med       Date:  1986-01
View more
  2 in total

1.  A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.

Authors:  Hiroo Yokozeki; Tomoko Fujimoto; Yoichiro Abe; Masaru Igarashi; Akiko Ishikoh; Tokuya Omi; Hiroki Kanda; Hiroto Kitahara; Miwako Kinoshita; Ichiro Nakasu; Naoko Hattori; Yuki Horiuchi; Ryuji Maruyama; Haruko Mizutani; Yoshiyuki Murakami; Chiharu Watanabe; Akihiro Kume; Takaaki Hanafusa; Masamitsu Hamaguchi; Akira Yoshioka; Yuriko Egami; Keizo Matsuo; Tomoko Matsuda; Motoki Akamatsu; Toshiyuki Yorozuya; Shinichi Takayama
Journal:  J Dermatol       Date:  2021-01-07       Impact factor: 4.005

2.  A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis.

Authors:  Tomoko Fujimoto; Yoichiro Abe; Masaru Igarashi; Akiko Ishikoh; Tokuya Omi; Hiroki Kanda; Hiroto Kitahara; Miwako Kinoshita; Ichiro Nakasu; Naoko Hattori; Yuki Horiuchi; Ryuji Maruyama; Haruko Mizutani; Yoshiyuki Murakami; Chiharu Watanabe; Akihiro Kume; Takaaki Hanafusa; Masamitsu Hamaguchi; Akira Yoshioka; Yuriko Egami; Keizo Matsuo; Tomoko Matsuda; Motoki Akamatsu; Toshiyuki Yorozuya; Shinichi Takayama; Hiroo Yokozeki
Journal:  J Dermatol       Date:  2021-05-26       Impact factor: 4.005

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.